To clarify the role of thrombopoietin (c-Mpl ligand, TPO) in ‘hypersplenic’ thrombocytopenia, we used an enzyme-linked immunosorbent assay to examine changes in serum TPO levels accompanied with splenectomy in 6 patients with liver cirrhosis, 4 patients with gastric cancer, and 2 patients with lymphoid malignancies. We also measured serum levels of other thrombopoietic cytokines such as interleukin-6 (IL-6) and erythropoietin. Platelet counts reached a maximum at day 14 after splenectomy in all subjects. In patients with liver cirrhosis, a lower elevation of platelet counts was observed compared with that in patients with gastric cancer. Serum TPO levels gradually elevated after splenectomy and reached a maximum 3.5 days after splenectomy in noncirrhotic patients, whereas peak serum TPO levels were delayed until day 7 in the cirrhosis group. IL-6 and erythropoietin showed similar kinetics between cirrhotic and noncirrhotic patients. These findings suggest that transient thrombocytosis after splenectomy may be associated with an alteration in the site of TPO catabolism by platelets from spleen to the blood and that deterioration of TPO production may play a role in thrombocytopenia in liver cirrhosis.

Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419–431.
de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg LA, Goeddel DV, Eaton DL: Stimulation of megakaryopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533–538.
Nomura S, Ogami K, Kawamura K, Tsukamoto Y, Kudo Y, Kanakura Y, Kitamura Y, Miyazaki H, Kato T: Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997;25:565–572.
Sungaran R, Markovic B, Chong BH: Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997;89:101–107.
Shimada Y, Kato T, Ogami K, Horie K, Kokubo A, Kudo Y, Maeda E, Sohma Y, Akahori H, Kawamura K, Miyazaki H: Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995;23:1388–1396.
Stoffel R, Wiestner A, Skoda RC: Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996;87:567–573.
Cohen-Solal K, Villeval J-L, Titeux M, Lok S, Vainchenker W, Wendling F: Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996;88:2578–2584.
de Sauvage FJ, Carver-Moore K, Luoh S-M, Ryan A, Dowd M, Eaton DL, Moore MW: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651–656.
Aster RH: Pooling of platelets in the spleen: Role in the pathogenesis of ‘hypersplenic’ thrombocytopenia. J Clin Invest 1966;45:645–657.
Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K: Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995;22:1682–1688.
Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996;87:2154–2161.
Singer K, Miller EB, Dameshek W: Hematologic changes following splenectomy in man, with particular reference to target cells, hemolytic index and lysolecithin. Am J Med Sci 1941;202:171–187.
Shimodaira S, Ishida F, Ichikawa N, Tahara T, Kato T, Kodaira H, Ito T, Tanaka E, Sodeyama T, Kiyosawa K, Kitano K: Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost 1996;76:549–555.
Martin T III, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA: Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285–288.
Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumoto A, Miyazaki H, Urabe A, Kato T: A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and patients with hematopoietic disorders. Br J Haematol 1996;93:783–788.
Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, Shiraga M, Honda S, Kanakura Y, Matsuzawa Y: Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93:704–706.
Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104–11108.
Kuter DJ, Rosenberg RD: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720–2730.
Ishida A, Miyakawa Y, Tanosaki R, Wakui M, Ueno H, Watanabe R, Awaya N, Tahara T, Kato T, Miyazaki H, Oda A, Kizaki M, Okamoto S, Ikeda Y: Circulating endogenous thrombopoietin, interleukin-3, interleukin-6 and interleukin-11 levels in patients undergoing allogeneic bone marrow transplantation. Int J Hematol 1996;65:61–69.
Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE: Stimulation of Megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673–681.
Toghill PJ, Green S: Splenic influences on the blood in chronic liver disease. Q J Med 1979;192:613–625.
Carver-Moore K, Broxmeyer HE, Luoh S-M, Cooper S, Peng J, Burstein SA, Moore MW, de Sauvage FJ: Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996;88:803–808.
Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M, Gotoh M, Kishimoto T, Mori T: Interleukin-6 as a new indicator of inflammatory status: Detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992;111:201–209.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.